A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

June 24, 2026 updated by: Day One Biopharmaceuticals, Inc.

A Phase 1/2, First-in-human, Multicenter Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

A Study of Emi-Le in Participants with Solid Tumors

Study Overview

Detailed Description

This first-in-human (FIH) study will test the safety, side effects, and antitumor activity of a drug called Emi-Le ((Emiltatug Ledadotin, formerly XMT-1660). A side effect is anything a drug does to the body besides treating the disease.

Participants in the study will have cancer that has come back after a period of time during which the cancer could not be detected (recurrent), spread in the body near where it started (advanced) or spread through the body (metastatic).

The study will have three parts. The first part called Dose Escalation, will find out how much Emi-Le should be given to participants. The second part called Dose Expansion, will use the dose found in the first part to find out how safe Emi-Le is and if it works to treat solid tumors. The third part, the Phase 2 part of the trial, called EMBLEM-1, will find out if Emi-Le works to treat aggressive Adenoid Cystic Carcinoma and continue to check how safe Emi-Le is.

Study Type

Interventional

Enrollment (Estimated)

360

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Arizona
      • Phoenix, Arizona, United States, 85054
        • Recruiting
        • Mayo Clinic Comprehensive Cancer Center
        • Principal Investigator:
          • Felipe Batalini, MD
        • Contact:
          • Felipe Batalini, MD
    • California
      • Orange, California, United States, 92868
        • Recruiting
        • UC Irvine Health-Chao Family Comprehensive Cancer Center
        • Contact:
          • Ritesh Parajuli
        • Principal Investigator:
          • Ritesh Parajuli
      • San Francisco, California, United States, 94158
        • Recruiting
        • UCSF Helen Diller Family Comprehensive Cancer Center
        • Principal Investigator:
          • Laura Huppert, MD
        • Contact:
          • Laura Huppert, MD
      • Santa Monica, California, United States, 90404
        • Recruiting
        • UCLA David Geffen School of Medicine, Division of Hematology/Oncology
        • Contact:
          • Nicholas McAndrew, MD
        • Principal Investigator:
          • Nicholas McAndrew, MD
    • Florida
      • Jacksonville, Florida, United States, 32224
        • Recruiting
        • Mayo Clinic - Jacksonville
        • Principal Investigator:
          • Pooja Advani, MD
        • Contact:
          • Pooja Advani, MD
      • Sarasota, Florida, United States, 34232
        • Recruiting
        • Florida Cancer Specialists
        • Contact:
          • Judy Wang
        • Principal Investigator:
          • Judy Wang
      • Tampa, Florida, United States, 33612
        • Recruiting
        • Moffitt Cancer Center
        • Contact:
          • Hyo Han, MD
        • Principal Investigator:
          • Hyo Han, MD
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Recruiting
        • Winship Cancer Institute, Emory University
        • Contact:
          • Kevin Kalinsky, MD
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Recruiting
        • Northwestern University
        • Contact:
          • Patricia Robinson, MD
        • Principal Investigator:
          • Patricia Robinson, MD
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Recruiting
        • Dana-Farber Cancer Institute
        • Contact:
          • Antonio Giordano, MD, PhD
      • Boston, Massachusetts, United States, 02215
        • Recruiting
        • Beth Israel Deaconess Medical Center
        • Contact:
          • Gerburg Wulf, MD
        • Principal Investigator:
          • Gerburg Wulf, MD
    • Michigan
      • Detroit, Michigan, United States, 48202
        • Recruiting
        • Henry Ford Health Hospital
        • Contact:
          • Amy Weise, MD
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Recruiting
        • Mayo Clinic - Rochester
        • Principal Investigator:
          • Roberto Leon-Ferre, MD
        • Contact:
          • Roberto Leon-Ferre, MD
    • Nevada
      • Las Vegas, Nevada, United States, 89169
        • Recruiting
        • Comprehensive Cancer Centers of Nevada
        • Principal Investigator:
          • Liawaty Ho, MD
        • Contact:
          • Liawaty Ho, MD
    • New York
      • New York, New York, United States, 10065
        • Recruiting
        • Memorial Sloan Kettering Cancer Center
        • Contact:
          • Nour Abuhadra, MD
      • New York, New York, United States, 10016
        • Recruiting
        • New York University Langone Health
        • Contact:
          • Nancy Chan, MD
      • New York, New York, United States, 10029
        • Recruiting
        • Ichan School of Medicine at Mount Sinai
        • Contact:
          • Amy Tiersten
        • Principal Investigator:
          • Amy Tiersten
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73104
        • Recruiting
        • Stephenson Cancer Center Oklahoma University Health
        • Principal Investigator:
          • Debra Richardson, MD
        • Contact:
          • Debra Richardson, MD
    • South Dakota
      • Sioux Falls, South Dakota, United States, 57105
        • Recruiting
        • Avera Cancer Institute
        • Contact:
          • David C. Starks, MD
        • Principal Investigator:
          • David C. Starks, MD
    • Tennessee
      • Nashville, Tennessee, United States, 37203
        • Recruiting
        • Sarah Cannon Research Institute (SCRI)
        • Contact:
          • Erika P Hamilton, MD
    • Texas
      • Dallas, Texas, United States, 75251
        • Recruiting
        • Texas Oncology, P.A.
        • Principal Investigator:
          • Joyce O'Shaughnessy, MD
      • Houston, Texas, United States, 77030
        • Recruiting
        • MD Anderson
        • Principal Investigator:
          • Funda Meric-Bernstam
        • Contact:
          • Funda Meric-Bernstam
    • Utah
      • Salt Lake City, Utah, United States, 84112
        • Recruiting
        • Huntsman Cancer Institute
        • Contact:
          • Kristen Kelley, MD
        • Principal Investigator:
          • Kristen Kelley, MD
    • Virginia
      • Fairfax, Virginia, United States, 22031
        • Recruiting
        • NEXT Oncology Virginia
        • Contact:
          • Alex Spira, MD, PhD
    • Washington
      • Seattle, Washington, United States, 09109
        • Recruiting
        • Fred Hutchinson Cancer Center
        • Contact:
          • Jennifer Specht, MD
      • Spokane, Washington, United States, 99208
        • Recruiting
        • Summit Cancer Centers
        • Contact:
          • Arvind Chaudhry, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Recurrent or advanced solid tumor and has disease
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Participants in DES must have at least one measurable disease (target) lesion as defined by RECIST version 1.1.
  • Tumor tissue, either archival or from a fresh tumor biopsy, available for testing or be willing to undergo a minimally invasive tumor biopsy to obtain tumor tissue for local testing, if not medically contraindicated, prior to Cycle 1 Day 1
  • Brain magnetic resonance imaging (MRI) during the Screening period unless obtained within 30 days prior to Screening (based on standard clinical care), if they meet either of the following criteria:

    1. All participants with TNBC
    2. Participants with a history of brain metastases or with neurologic symptoms or signs suspicious for brain metastases.

Exclusion Criteria:

  • Prior treatment with an Antibody Drug Conjugate (ADC) containing an auristatin payload. Prior treatment with another ADC containing other payloads is allowed.
  • Major surgery within 28 days of starting study treatment, systemic anticancer therapy within the time period of 28 days or 5 half-lives of the prior therapy before starting study treatment (14 days or 5 half-lives for small molecule targeted therapy), whichever is less, or palliative radiation therapy to the chest within 3 months of starting study treatment or to other anatomic sites within 14 days of starting study treatment.
  • Diagnosis of additional malignancy that required active treatment (including surgery, systemic therapy, and radiation) within 2 years prior to screening, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix.
  • Untreated CNS metastases (including new and progressive brain metastases), history of leptomeningeal metastasis or carcinomatous meningitis.
  • Prior B7-H4 targeted treatment.
  • History of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other clinically significant liver diseases.
  • Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could increase the risk of serious adverse events (SAEs) or interfere with per-protocol evaluations, in the judgment of either the Sponsor or the Investigator.
  • Clinically significant cardiovascular disease
  • Active keratitis (inflammation of the cornea of the eye)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Emi-Le
Single arm Emi-Le alone (monotherapy)
Emi-Le will be administered through a vein in your arm or port catheter (intravenously)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency of adverse events that are considered dose-limiting toxicities (DLTs) and associated with Emi-Le during the first cycle of treatment (Dose Escalation)
Time Frame: 17 months
Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of Emi-Le
17 months
Incidence of adverse events (Dose Escalation and Dose Expansion)
Time Frame: 3 years
Assess the safety and tolerability of Emi-Le by determining the number of patients with adverse events from date of first dose to 60 days post last dose
3 years
Objective Response Rate (ORR) (Dose Expansion and EMBLEM-1)
Time Frame: approximately 3 years
The percentage of patients with a best overall response of complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
approximately 3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective Response Rate (ORR) (Dose Escalation)
Time Frame: Up to approximately 3 years
The percentage of patients with a best overall response of complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Up to approximately 3 years
Duration of response (DOR) (Dose Escalation, Dose Expansion, and EMBLEM-1)
Time Frame: Up to approximately 3 years
The time from when response criteria are first met until disease progression or death in participants who achieve a complete or partial response
Up to approximately 3 years
Maximum observed plasma concentration of Emi-Le and payload (Cmax) (Dose Escalation and Dose Expansion)
Time Frame: Up to approximately 3 years
Cmax is the maximum concentration determined from the measured concentrations in plasma
Up to approximately 3 years
Area under the concentration-time curve of Emi-Le and payload (AUC) (Dose Escalation and Dose Expansion)
Time Frame: Up to approximately 3 years
Area under the concentration-time curve for the last measurable concentration (AUC0-last) will be assessed as data permit
Up to approximately 3 years
Antidrug antibodies (ADAs) and neutralizing antibodies (NAbs) (Dose Escalation, Dose Expansion, and EMBLEM-1)
Time Frame: Up to approximately 3 years
Assess the development of ADAs and NAbs to Emi-Le
Up to approximately 3 years
Assess the overall survival (OS) of patients treated with Emi-Le (Dose Escalation, Dose Expansion, and EMBLEM-1)
Time Frame: Up to approximately 3 years
The time from the date of first dose of study treatment to the date of death due to any cause
Up to approximately 3 years
Incidence of adverse events (EMBLEM-1)
Time Frame: 3 years
Assess the safety and tolerability of Emi-Le by determining the number of patients with adverse events from date of first dose to 60 days post last dose
3 years
Progression-free survival (PFS) (EMBLEM-1)
Time Frame: Up to approximately 3 years
The time from the date of first dose of study treatment until the first date at which disease progression is objectively documented or date of death due to any cause, whichever occurs first
Up to approximately 3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Robert Burger, MD, Day One Biopharmaceuticals, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 15, 2022

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

May 2, 2022

First Submitted That Met QC Criteria

May 11, 2022

First Posted (Actual)

May 17, 2022

Study Record Updates

Last Update Posted (Actual)

June 29, 2026

Last Update Submitted That Met QC Criteria

June 24, 2026

Last Verified

June 1, 2026

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe